When to Raise Our White Flag—A Discussion of Scope of Practice in a Resource Scarce World
CASE: Thomas is a 13-year-old boy with autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), generalized anxiety disorder, separation anxiety disorder, and major depressive disorder who presented for a follow-up to his developmental and behavioral pediatrician (DBP). His mother describes an increase in symptoms of anxiety and depression for the last 6 weeks, accompanied by suicidal ideation and thoughts of self-mutilation. Before this increase in symptoms, he had been doing well for the last several months with the exception of increasing weight gain, and Abilify was decreased from 5 mg to 2.5 mg at...
Source: Journal of Developmental and Behavioral Pediatrics - February 1, 2020 Category: Child Development Tags: Challenging Case Source Type: research

Drugs for ADHD
Date: January 27, 2020 Issue #:  1590Summary:  Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of s...
Source: The Medical Letter - January 2, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Adderall Adhansia ADHD Adzenys Amphetamine Aptensio Atomoxetine Biphentin Clonidine Concerta Cotempla daytrana Dexedrine Dexmethylphenidate Dextroamphetamine Dyanavel Evekeo Focalin Foquest Guanfacine Intuniv Jorn Source Type: research

Jornay PM - Evening-Dosed Methylphenidate for ADHD
Date: August 12, 2019 Issue #:  1578Summary:  The FDA has approvedJornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients>6 years old.Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning. (Source: The Medical Letter)
Source: The Medical Letter - July 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Adhansia ADHD Aptensio Biphentin Concerta Contempla daytrana Dexmethylphenidate Focalin Foquest Jornay PM QuiliChew Quilivant Ritalin Source Type: research

Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD
Date: November 6, 2017 Issue #:  1533Summary:  The FDA has approved an extended-release orally disintegrating tablet formulation of methylphenidate (Cotempla XR-ODT– Neos Therapeutics) for once-daily treatment of attention-defi cit/hyperactivity disorder (ADHD) in children 6-17 years old.Cotempla XR-ODT is the first extended-release orally disintegrating tablet formulation of methylphenidate to become available in the US. (Source: The Medical Letter)
Source: The Medical Letter - October 30, 2017 Category: Drugs & Pharmacology Authors: admin Tags: ADHD Aptensio Concerta Contempla daytrana Dexmethylphenidate Focalin methyphenidate QuiliChew Quilivant Ritalin Source Type: research

First Person
Patient #1, the Partier: arrives at 0730, 6-year-old boy with history of extreme prematurity, developmental delay, and extreme hyperactivity. When asked if his Focalin had been taken that morning (obviously not!), mom replied, “Yes … uh … no … it's in the car!” Grandmother stumbled into the room part way into the exam, clearly intoxicated. Said child then proceeds to start wildly swinging some Mardi Gras beads as he runs around the room. Mother threatens to send the little fellow home with the doctor, who replies, “Oh no, I don't think that's a good idea.” The tech is heard to m...
Source: Journal of AAPOS - April 1, 2014 Category: Opthalmology Tags: Major Articles Source Type: research

Trends in attention deficit hyperactivity disorder drugs consumption, Israel, 2005–2012
ConclusionsThere has been a drastic rise in ADHD drugs consumption in Israel over 2005–2012. This has been associated with substantial reduction in cost and changes in the pattern of prescribing that characterized by increased prescription of high‐dose long‐acting preparations of ADHD drugs and decreased prescription of their low‐dose, short‐acting formulations. Copyright © 2014 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - March 1, 2014 Category: Drugs & Pharmacology Authors: Alexander M. Ponizovsky, Eli Marom, Israel Fitoussi Tags: Original Report Source Type: research